Posts Tagged ‘P2D Bioscience’

Advinus Therapeutics and P2D Bioscience Enter Into a Research and Development Collaboration for Attention Deficit Hyperactivity Disorder (ADHD)

Advinus Therapeutics Ltd., a drug discovery and development company, and P2D Bioscience, a CNS-focused specialty pharmaceutical company, have initiated a research and development collaboration to develop therapies for Attention Deficit Hyperactivity Disorder (ADHD).

Visit to learn more.


07 2012

P2D Bioscience Receives NIH Funding to Develop Drugs for Lung Disease

P2D Bioscience has received a $320,000 grant from the U.S. National Heart, Lung and Blood Institute. The purpose of this grant is to develop a novel class of anti-inflammatory drugs specifically targeting lung diseases, including acute lung injury/acute respiratory distress syndrome, chronic obstructive pulmonary disease (COPD) and asthma.

Click here to read the entire release.


07 2011

P2D Bioscience Awarded NIH Grant to Develop PD2007

P2D Bioscience has received a $1.5 million grant from the National Institutes of Health (NIH) to develop its lead dopamine transport inhibitor, PD2007, through IND safety and toxicology studies for future use in humans. More than a decade of preclinical testing and numerous scientific publications indicate PD2007’s efficacy at inhibiting dopamine transport in multiple brain regions.

Click here to read the entire release.


06 2011

P2D Bioscience Announces Enhanced Patent Position for Lead ADHD Drug

P2D Bioscience’s lead compounds, PD2005 and PD2007, have received U.S. and Canadian patent protection for treating Attention Deficit/Hyperactivity Disorder (ADHD). The patents contain ADHD-use claims for the entire family of P2D’s first-in-class dopamine transport inhibitors, including PD2005 and PD2007.

Click here to read entire release


04 2011